8-K: Nutriband Authorizes New Convertible Preferred Stock and Declares Dividend

Nutriband Inc. has amended its Articles of Incorporation to authorize a new series of convertible preferred stock and declared a dividend of these shares to existing common shareholders.

Summary

• The Board of Directors of Nutriband Inc. approved an amendment to the Articles of Incorporation on July 9, 2025, to authorize 2,788,678 shares of Series A Convertible Preferred Stock, with a par value of $0.001 per share.
• The Board also authorized a preferred stock dividend, issuing one share of Series A Preferred Stock for each four shares of common stock owned by holders, with a record date of July 25, 2025.
• Each share of Series A Preferred Stock will be convertible at the option of the holder into one share of Common Stock following the date of approval for commercial sale by the Federal Drug Administration (FDA) of the Company's transdermal pharmaceutical products based on its AVERSA abuse deterrent technology.
• Holders of Series A Preferred Stock are eligible for dividends declared by the Board, both specifically for Series A Preferred and for the common stock class.
• The Series A Preferred Stock is generally non-voting, but holders vote together with common stock on certain matters, with votes equal to their conversion ratio, and have class-specific voting rights for amendments to their Statement of Designations.

Sentiment

Score: 6

Explanation: The announcement is generally neutral to positive. It represents a strategic corporate action that could benefit shareholders if the underlying FDA approval is achieved, but also introduces potential future dilution. The dividend itself is a positive for current shareholders.

Positives

• Existing common shareholders will receive a dividend of Series A Preferred Stock, potentially increasing their equity stake in the company.
• The Series A Preferred Stock offers a potential upside as it becomes convertible into common stock upon certain events, notably FDA approval of the AVERSA-based products.
• Holders of Series A Preferred Stock are eligible to receive dividends declared by the Board, aligning their interests with both preferred and common stock holders.

Negatives

• The Series A Preferred Stock is generally non-voting, which limits the direct influence of preferred shareholders on most corporate decisions.
• Future conversion of the Series A Preferred Stock into common stock could lead to dilution for existing common shareholders, depending on the number of shares converted.
• The primary conversion trigger, FDA approval of AVERSA products, is a regulatory hurdle and its timing and outcome are uncertain.

Risks

• The convertibility of the Series A Preferred Stock is contingent on FDA approval of the Company's AVERSA abuse deterrent transdermal technology products, which is not guaranteed and could be subject to delays.
• Potential dilution of common stock value if a significant number of Series A Preferred shares are converted into common stock, especially if conversion occurs under conditions other than FDA approval.
• The non-voting nature of the Series A Preferred Stock (except for specific circumstances) means holders will have limited direct influence on corporate governance and strategic decisions.

Future Outlook

The Series A Preferred Stock will become convertible into common stock at the holder's option following FDA approval for commercial sale of the Company's transdermal pharmaceutical products based on its AVERSA abuse deterrent technology. Other conversion events include five years from the IPO date, acquisition by a third party, a change of control (acquiring at least a 40% equity position), filing of the first Form 10-K reporting consolidated net income of at least $1,000,000, achieving a market capitalization of at least $200,000,000 or a public float of at least $75,000,000, or a determination by the compensation committee (or other committee composed solely of independent directors) not earlier than two years from the IPO date.

Management Comments

• Gareth Sheridan, Chief Executive Officer, signed the report on behalf of Nutriband Inc.

Industry Context

This corporate action is typical for pharmaceutical companies that rely heavily on regulatory milestones, such as FDA approvals, to unlock value. The creation of convertible preferred stock tied to such milestones can be a strategy to manage capital structure and incentivize long-term holding while awaiting key product developments.

Corporate Governance

Stakeholder Impact

• Shareholders: Will receive a dividend of Series A Preferred Stock, potentially increasing their overall equity position and offering future conversion opportunities tied to FDA approval and other milestones. However, future conversion could lead to dilution of common stock.
• Management: Gains flexibility in capital structure and a mechanism to reward existing shareholders while awaiting key product development milestones.

Next Steps

• The Company awaits FDA approval for commercial sale of its transdermal pharmaceutical products based on AVERSA abuse deterrent technology, which is a key trigger for the convertibility of the Series A Preferred Stock.
• Shareholders will receive the preferred stock dividend on or after the July 25, 2025 record date.

Key Dates

Recommendation

Keywords

Nutriband Inc., Series A Convertible Preferred Stock, Preferred Stock Dividend, SEC Filing, Form 8-K, Corporate Governance, Capital Structure, FDA Approval, AVERSA Technology, Transdermal Pharmaceutical Products, Shareholder Dividend, Stock Conversion, NTRB